Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on International Tech Times.
Press releases published on May 22, 2025
Daktronics to Participate in the 22nd Annual Craig-Hallum Institutional Investor Conference on May 28th
GlobeNewswire
·
May 22, 2025
BROOKINGS, S.D., May 22, 2025 (GLOBE NEWSWIRE) -- Daktronics, Inc. (Nasdaq: DAKT), a leading global designer and manufacturer of best-in-class dynamic video communication displays and control systems for customers worldwide today announced that Brad …
ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy at ASCO 2025
GlobeNewswire
·
May 22, 2025
ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy at ASCO 2025 ICT01 in combination with azacitidine and venetoclax (Aza-Ven) achieves unprecedented high remission rates overall and across molecular subtypes in newly …
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
GlobeNewswire
·
May 22, 2025
CAMBRIDGE, Mass. and TOKYO, Japan and PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today announced new positive results from the pivotal Phase 2b …
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
GlobeNewswire
·
May 22, 2025
An oral presentation at ASCO …
Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting
GlobeNewswire
·
May 22, 2025
Preliminary efficacy analysis from the elacestrant plus everolimus and ribociclib cohorts of the ELEVATE study, along with updated safety data from additional cohorts of elacestrant plus targeted therapy combination arms, will be presented. These data …
Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025
GlobeNewswire
·
May 22, 2025
· BI 765063 in combination with programmed cell death-1 (PD1) inhibitor antibody ezabenlimab + cetuximab demonstrated a well-tolerated safety profile and potentially promising efficacy signals as second-line treatment in patients with recurrent/ …
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
GlobeNewswire
·
May 22, 2025
Phase 2 (Actuate-1801 Part 3B) trial topline results meet primary endpoint of improved survival in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) Oral presentation at the American Society of Clinical Oncology (ASCO) …
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
May 22, 2025
CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatellite stable colorectal cancer …
Avidicure to Present Preclinical Data from Lead TROP2-targeting Multifunctional Antibody Program at the 2025 American Society of Clinical Oncology Annual Meeting
GlobeNewswire
·
May 22, 2025
AMSTERDAM, May 22, 2025 (GLOBE NEWSWIRE) -- Avidicure, a biotechnology company pioneering an entirely new dual agonistic, multifunctional antibody modality with broad applicability in oncology, today announced its upcoming presentation at the 2025 American …
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
GlobeNewswire
·
May 22, 2025
NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting
GlobeNewswire
·
May 22, 2025
LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, …
Acceleware Ltd. Reports First Quarter 2025 Financial and Operating Results
GlobeNewswire
·
May 22, 2025
CALGARY, Alberta, May 22, 2025 (GLOBE NEWSWIRE) -- Acceleware® Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE), an advanced electromagnetic (“EM”) heating company with highly scalable solutions for large industrial applications, today announced its …
SABIO DISRUPT LONDON 2025: CX LEADERS SHOWCASE AI INNOVATION AND TRANSFORMATION SUCCESS
EIN Presswire
·
May 22, 2025
Industry giants in CX converged on London this week for Disrupt 2025, the latest leg in Europe's premier digital transformation and innovation programme LONDON, UNITED KINGDOM, May 22, 2025 /EINPresswire.com/ -- Industry giants in customer experience ( …
ImPact Biotech Announces Late-Breaking Podium Presentation at ASCO 2025 Highlighting ENLIGHTED Study Interim Analysis
GlobeNewswire
·
May 22, 2025
-- Company to present interim update from ENLIGHTED Phase 3 Study in LG UTUC following assessment of 50% of targeted total evaluable patient enrollment -- TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology …
Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma
GlobeNewswire
·
May 22, 2025
First results to be presented in two ASCO oral presentations Data in both combinations demonstrate high response rates TARRYTOWN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial results from two …
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
GlobeNewswire
·
May 22, 2025
Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodies Long-term outcomes and survival data for Ziihera® (zanidatamab-hrii), which was developed using Azymetric™, to be presented at …
COOFANDY Marks 10th Anniversary with Dual Silver Awards at Berlin and New York Product Design Competitions
GlobeNewswire
·
May 22, 2025
New York, NY, May 22, 2025 (GLOBE NEWSWIRE) -- As COOFANDY celebrates its 10th anniversary in 2025, the brand has reached an exciting new milestone: The COOFANDY Men’s Short-Sleeve Casual Shirts have earned Silver Awards at both the 2025 Berlin Design …
A new passive income solution for 2025: Efficiently participate in Bitcoin and cryptocurrency mining with PairMiner
GlobeNewswire
·
May 22, 2025
Washington, D.C., USA, May 22, 2025 (GLOBE NEWSWIRE) -- PAIRMiner, an advanced platform offering mining power services. Recently, Bitcoin has made a strong comeback, with its price soaring and reigniting global investors' passion and confidence in …
Best Dogecoin & Bitcoin Mining Site of 2025: FioBit Launches the Most Profitable AI Cloud Miner to Help Crypto Investors Earn Faster
GlobeNewswire
·
May 22, 2025
Sydney, Australia, May 22, 2025 (GLOBE NEWSWIRE) -- As the cryptocurrency market continues to mature in 2025, cloud mining has emerged as a cornerstone for both beginners and experienced investors seeking passive income through Bitcoin(BTC) and Dogecoin( …
Clear Blue Technologies International to provide Corporate Update and Report Q1 2025 Financial Results and Host Conference Call on Thursday, May 29th, 2025
GlobeNewswire
·
May 22, 2025
TORONTO, May 22, 2025 (GLOBE NEWSWIRE) -- Clear Blue Technologies International Inc. (TSXV: CBLU) the Smart Off-Grid™ Company, today announces that it will provide a corporate update and also report financial results for its first quarter 2025 on Wednesday …